BVA helps end the debate by taking the guesswork out of determining a patient’s
volume status to significantly improve multiple measures of patient outcomes.
Propensity matched-control trial in community hospital | n = 245, Mixed HFpEF/HFrEF
Prospective randomized control trial in surgical ICU | n = 100, 70% Septic Shock/Sepsis/40% ARDS
36 Hour Earlier
44% Change in Treatment
Strategy Versus Standard Care
Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF
Well above the 0.227 previously reported
Than far below the threshold of $50,000
As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.
Call us at 865-425-0555.
Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.